1-20 of 39
Rajneesh Nath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Stuart Seropian, James M. Foran, Boglarka Gyurkocza, Rajneesh Nath, Hannah Choe, Mark R. Litzow, Nebu Koshy, Patrick J. Stiff, Ben K. Tomlinson, Sunil Abhyankar, Sameem Abedin, George Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Joanna Jamieson, Margarida Magalhaes-Silverman, Koen Van Besien, Michael W. Schuster, Arjun D. Law, Sebastian A. Mayer, Hillard M. Lazarus, Jennifer Spross, Kate L Li, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, Brenda M. Sandmaier, John Pagel, Sergio A. Giralt, Avinash Desai, Camille N. Abboud
Journal: Blood
Blood (2023) 142 (Supplement 1): 2159.
https://doi.org/10.1182/blood-2023-187433
Published: 2023
Journal Articles

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Frederick L. Locke, Javier L. Munoz, Michael T. Tees, Lazaros J. Lekakis, Herbert A. Eradat, Sven de Vos, Rajneesh Nath, Don A. Stevens, Shahbaz A. Malik, Geoffrey P. Shouse, Mehdi Hamadani, Olalekan O. Oluwole, Miguel-Angel Perales, David B. Miklos, Anh Nguyen, Amy Feng, Lynn Navale, Elaine Murray, Greg P. Kaufman, Kazuharu Kai, John B. Le Gall, Sattva S. Neelapu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2095.
https://doi.org/10.1182/blood-2023-189196
Published: 2023
Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Mark R. Litzow, George Chen, Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Camille N. Abboud, Nebu Koshy, Ben K. Tomlinson, Sunil Abhyankar, James M. Foran, Sameem Abedin, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Joanna Jamieson, Margarida Magalhaes-Silverman, Koen Van Besien, Michael W. Schuster, Arjun D. Law, Sebastian A. Mayer, Hillard M. Lazarus, Eugene Leung, Ming-Kai Chen, Mona Natwa, Jennifer Spross, Kate L Li, Norman Nagl, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, Brenda M. Sandmaier, John Pagel, Sergio A. Giralt, Avinash Desai, Richard L. Wahl, Neeta Pandit-Taskar, Patrik Brodin, Patrick J. Stiff
Journal: Blood
Blood (2023) 142 (Supplement 1): 3529.
https://doi.org/10.1182/blood-2023-189040
Published: 2023
Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Hannah Choe, Ben K. Tomlinson, Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Mark R. Litzow, Camille N. Abboud, Patrick J. Stiff, Sunil Abhyankar, James M. Foran, Sameem Abedin, George Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Joanna Jamieson, Margarida Magalhaes-Silverman, Koen Van Besien, Michael W. Schuster, Arjun D. Law, Sebastian A. Mayer, Hillard M. Lazarus, Jennifer Spross, Kate L Li, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, Brenda M. Sandmaier, John Pagel, Sergio A. Giralt, Avinash Desai, Nebu Koshy
Journal: Blood
Blood (2023) 142 (Supplement 1): 469.
https://doi.org/10.1182/blood-2023-182177
Published: 2023
Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Alison R Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A Chow, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon
Journal: Blood
Blood (2023) 142 (Supplement 1): 105.
https://doi.org/10.1182/blood-2023-180952
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Tanya Siddiqi, David G Maloney, Saad S. Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San-San Ou, Neha Rane, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 330.
https://doi.org/10.1182/blood-2023-179529
Published: 2023
Journal Articles

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4620–4622.
https://doi.org/10.1182/blood-2022-158231
Published: 2022
Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Nebu V. Koshy, Patrick Stiff, Camille Abboud, Sr., Benjamin Tomlinson, Sunil Abhyankar, Parameswaran Hari, Zaid S. Al-Kadhimi, George L. Chen, Mitchell Sabloff, Johnnie J. Orozco, James M. Foran, Partow Kebriaei, Katarzyna Joanna Jamieson, Margarida Magalhaes Magalhaes-Silverman, Koen van Besien, Michael W. Schuster, Arjun Law, Moshe Levy, Hillard M Lazarus, Sergio A Giralt, Mark S. Berger, Jennifer A Spross, Avinash G Desai, Vijay Reddy, John M. Pagel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1791.
https://doi.org/10.1182/blood-2021-148497
Published: 2021
Journal Articles

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

Sattva S. Neelapu, Rajneesh Nath, Javier Munoz, Michael Tees, David B. Miklos, Matthew J. Frank, Shahbaz A. Malik, Don Stevens, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Anh Nguyen, Frederick L. Locke
Journal: Blood
Blood (2021) 138 (Supplement 1): 3878.
https://doi.org/10.1182/blood-2021-146038
Published: 2021
Journal Articles

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Caitlin Costello, Ben A Derman, Mehmet Hakan Kocoglu, Abhinav Deol, Abbas Abbas Ali, Tara Gregory, Bhagirathbhai Dholaria, Jesus G Berdeja, Adam D Cohen, Krina K. Patel, David S. Siegel, Rajneesh Nath, Katherine McArthur, Joanne McCaigue, Christopher E Martin, Majid Ghoddusi, Hamid Namini, Eric M. Ostertag, Matthew A. Spear, Rajesh Belani, Nina Shah
Journal: Blood
Blood (2021) 138 (Supplement 1): 3858.
https://doi.org/10.1182/blood-2021-151672
Published: 2021
Journal Articles

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

Manish R. Patel, Varun Monga, Shekeab Jauhari, Don Stevens, Lucia Masarova, Meredith McKean, David Mauro, John Viscusi, Peggy Scherle, Neha Bhagwat, Andrew Moore, William Sun, Rachel Chiaverelli, Eric Mintah, Rajneesh Nath, Eytan M. Stein, Neil Palmisiano, Grerk Sutamtewagul, Srdan Verstovsek
Journal: Blood
Blood (2021) 138 (Supplement 1): 2609.
https://doi.org/10.1182/blood-2021-150938
Published: 2021
Journal Articles

An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ® ) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma

Sumit Madan, Al-Ola Abdallah, Andrew J. Cowan, William I. Bensinger, Jens Hillengass, Xavier Leleu, Eva Medvedova, Caitlin Costello, Brea Lipe, Henning Schade, Rajneesh Nath, Liping Laura Sun
Journal: Blood
Blood (2021) 138 (Supplement 1): 1654.
https://doi.org/10.1182/blood-2021-148176
Published: 2021
Journal Articles

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Michaela Liedtke, Surbhi Sidana, Jeffrey V. Matous, Saurabh Chhabra, Olalekan O. Oluwole, Shahbaz A. Malik, Shaji Kumar, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Sundar Jagannath, Myo Htut, Noopur S. Raje, David S. Siegel, Erin E. Karski, Wade Lovelace, Afrodite Lourbakos, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 651.
https://doi.org/10.1182/blood-2021-145572
Published: 2021
Journal Articles

HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Henning Schade, MD, Sumit Madan, MD, Eva Medvedova, MD, Rajneesh Nath, MD, Lisa Knapp, Bryan Lemon, PhD, Liping Laura Sun, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10.
https://doi.org/10.1182/blood-2020-136012
Published: 2020
Journal Articles

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS, Jeffrey V. Matous, MD, Michaela Liedtke, MD, Surbhi Sidana, MD, Shahbaz Malik, MD, Rajneesh Nath, MD, Olalekan O. Oluwole, MBBS, MPH, Erin E. Karski, Wade Lovelace, Xiangdong Zhou, PhD, Srinand Nandakumar, PhD, Arun Balakumaran, MD PhD, Parameswaran Hari, MD MRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-140641
Published: 2020
Journal Articles

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Hannah Choe, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, Edward Agura, MD, Mark Litzow, MD, Benjamin K. Tomlinson, MD, George L. Chen, MD, Parameswaran Hari, MD MRCP, Johnnie Orozco, MD, Zaid S. Al-Kadhimi, MD, Camille Abboud, MD, Koen Van Besien, MD PhD, Mitchell Sabloff, MSc,MDFRCPC, Margarida Magalhaes Magalhaes-Silverman, James M. Foran, MD, Michael W. Schuster, MD, Partow Kebriaei, MD, Moshe Levy, MD, Hillard M Lazarus, MD, Sergio A. Giralt, MD, Qing Liang, PhD, Mark S. Berger, MD, Vijay Reddy, MDPhD, John M. Pagel, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-134624
Published: 2020
Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Hannah Choe, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, Edward Agura, MD, Mark Litzow, MD, Benjamin K. Tomlinson, MD, George L. Chen, MD, Parameswaran Hari, MD MRCP, Johnnie Orozco, MD, Zaid S. Al-Kadhimi, MD, Camille Abboud, MD, Koen Van Besien, MD PhD, Mitchell Sabloff, MSc,MDFRCPC, Margarida Magalhaes Magalhaes-Silverman, James M. Foran, MD, Michael W. Schuster, MD, Partow Kebriaei, MD, Moshe Y. Levy, MD, Hillard M Lazarus, MD, Sergio A. Giralt, MD, Qing Liang, PhD, Mark S. Berger, MD, Vijay Reddy, MDPhD, John M. Pagel, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-134948
Published: 2020
Journal Articles

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Ben Buelow, MD PhD, Anita D'Souza, MBBS, Cesar Rodriguez, MD, Ravi Vij, MBBS, Rajneesh Nath, MD, Melinda Snyder, MS, Duy Pham, MBA, Ashwin Patel, PhD, Suhasini Iyer, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1874.
https://doi.org/10.1182/blood-2019-123220
Published: 2019
Journal Articles

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Rajneesh Nath, MD, Eileen M Geoghegan, Matthew L. Ulrickson, MD, Jennifer A Spross, MA, Renee H Lichtenstein, BA, Sandy Konerth, MS, Darrell R. Fisher, PhD, Qing Liang, PhD, Dale Ludwig, PhD BS, Vijay Reddy, MD PhD, Mark S. Berger, MD, Boglarka Gyurkocza, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1958.
https://doi.org/10.1182/blood-2019-128838
Published: 2019
Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Patrick J. Stiff, MD, Edward Agura, MD, Mark Litzow, MD, Ben Tomlinson, MD, Hannah K. Choe, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, George L. Chen, MD, Parameswaran Hari, MBBS, MD, Zaid S. Al-Kadhimi, MD, James M. Foran, MD, Johnnie Orozco, MD, Koen Van Besien, MD PhD, Mitchell Sabloff, MD, Partow Kebriaei, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio A Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD DSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 5642.
https://doi.org/10.1182/blood-2019-122776
Published: 2019